PAB

0.00%

0.6¢ patrys limited

Ann: Appendix 4E and 2023 Annual Report, page-5

First 5 Last

Share
Profile

Follow
Travis Cloke

880 Posts.

51

28/08/23

18:21

Post #: 69595816
Share

Originally posted by mattyedw: ↑

The 2023 Annual report is nothing that we did not know, very professional as one would expect and still a few quid in the bank....

The main differance is now PAB are pushing(it seems like every other sentance)2024 for first in human clinical trials, 12 months ago every other sentance was pushing 2023.....CAN WE GET THERE?????????????????????????

Imho it looks very unlikely, take this from the report captured below

"". This audit and review process is expected to be formally completed during the first half of FY2024. Once completed, Patrys and its CDMO intend to schedule a new production run to provide GMP-grade PAT-DX1 for the planned clinical trial. The final timing of this will be determined by the availability of a production slot with the CDMO. Patrys will inform shareholders of the timing for this run once the availability of a production slot has been confirmed by its CDMO. As a result of the investigation into this manufacturing issue, Patrys is now expecting to initiate its Phase 1 first-in-human study of PAT-DX1 in 2024. The timing of starting the trial will be determined by the availability of material from the new production run and the securing of approval from the Human Research Ethics Committees (HRECs) at the clinical trial sites.

The last Ann said we would have our final report on the failed production run in the coming months and then they could work on getting back to production and then initiating trials...
Now the audit and review process is expected to be formally completed during the first half of FY2024 which could take us upto 30th June 2024......?
Only when the audit is completed can we schedule a new production run, the timing of this is determined by the availability of a production run slot with our CDMO partners.....

PAB expecting to initiate Phase 1 studies in 2024......"" The timing of starting the trial will be determined by the availability of material from the new production run and the securing of approval from the Human Research Ethics Committees (HRECs) at the clinical trial sites. "" and this is after we have had to wait for the audit to be formilised and produced....

The way i see it is we have A very long road ahead and with long timelines for even our DX3 to go for its engineering run(which imho will be paramount to licencing/partnering) and DX-1 looking very thin to get to trials next year then 6yr lows and below look almost certain.....

Buying, holding and waiting at these lows is not a bad punt at all, but as most long termers are hugely in the red it is also soooooooooooooo frustrating..

Left field Ann on a deal/partnership?, not anytime soon imo as we would have had one ages ago if we didnt have problems with production..

Not much costs this quarter, but the next one(or possibly the one after)we will need plenty, at what price?

Expand

Agree. Matty. I think 2025 is more likely if the run is successful.

PAB Price at posting: 0.9¢ Sentiment: Hold Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The market's shrugged at China's stimulus measures all year. Why is this one different?

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

There are more pages in this discussion • 17 more messages in this thread...

First 5 Last

Add PAB (ASX) to my watchlist

(20min delay)
Last 0.6¢		Change 0.000(0.00%)		Mkt cap ! $12.34M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
3	1283356	0.6¢

Sellers (Offers)

Price($)	Vol.	No.
0.7¢	4958674	5

View Market Depth

No.	Vol.	Price($)
3	1283356	0.006
12	4399891	0.005
8	5414000	0.004
5	5899016	0.003
1	2520000	0.002

Price($)	Vol.	No.
0.007	4958674	5
0.008	1521890	4
0.009	1040280	4
0.010	355230	3
0.012	1292407	3

Last trade - 16.12pm 27/09/2024 (20 minute delay)

PAB (ASX) Chart

Day chart unavailable

Ann: Appendix 4E and 2023 Annual Report, page-5

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The market's shrugged at China's stimulus measures all year. Why is this one different?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

ACCC seeks Olam divestments before it can buy Namoi Cotton

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Appendix 4E and 2023 Annual Report, page-5

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The market's shrugged at China's stimulus measures all year. Why is this one different?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

ACCC seeks Olam divestments before it can buy Namoi Cotton

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News